Blazar

Blazar is a private French health-tech and bioinformatics company developing software and methods for biomedical and translational R&D workflows. The company originated in oncology and precision-medicine applications, with early emphasis on predicting response and resistance to cancer immunotherapies from clinical, molecular, and pathology data. Its current positioning focuses on preserving interpretability, traceability, and continuity of results as data, models, instruments, and pipelines evolve over time. Blazar markets its technology as an R&D-only, vendor-neutral platform that can be deployed in controlled institutional environments such as on-premise or private cloud settings. The company does not appear to be developing therapeutic assets; instead, it provides software infrastructure and analytical tooling for biomarker programs, AI-enabled pathology, and translational research.